CDKN2A and cancer: Instead, we consistently observed a significant difference in the abundance of the RB1 protein between these cancer cell lines with and without gain or loss of P16 function, indicating that there is a cell-specific posttranscriptional mechanism of P16 loss-mediated RB1 upregulation.